◈ Nootpedia
Compact view
Research pass: thorough Supplement · Capsule OPTIONAL-ADD MEDIUM

Apigenin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM

Strong mechanistic story (CD38/NAD+, GABA, senomorphic) but bioavailability is ~30% with rapid clearance — most users at 50 mg likely under-dose for systemic effects. Cheap insurance bet; would upgrade to STRONG-CANDIDATE if liposomal form used + bloodwork shows estradiol baseline isn't already low.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    Modest evidence for cognitive benefit in humans. Bioavailability concern means typical doses likely sub-therapeutic for systemic effects (NAD+, senomorphic). Best framed as "NAD+ preservation insurance + chamomile-tier evening calm" — not a primary cognitive driver. Cheap (~$6-30/mo) and low risk → low downside. Aromatase note matters less at 20yo with healthy testosterone production but worth tracking estradiol on June bloodwork. Verdict: optional, prefer liposomal form, won't be felt at 50 mg.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Same logic as above. CD38 climbs with age, so the NAD+ preservation thesis starts to gain traction here. Pair with NAD+ precursor for executives motivated by longevity.

  • 50+, mild cognitive decline / longevity-focus
    STRONG-CANDIDATE

    per Sinclair framework. CD38 elevation is more pronounced; NAD+ depletion more measurable; senomorphic effect more clinically meaningful. The longevity-stack thesis hits hardest here. Combine with NMN/NR as the canonical Sinclair pairing.

  • Anxiety-prone
    OPTIONAL-ADD

    Mild anxiolytic via GABA-A — useful as "always-on background" alongside acute tools (theanine, propranolol). Won't replace benzo / SSRI for clinical anxiety.

  • High athletic load, tested status (WADA-tested)
    OPTIONAL-ADD

    Not on any banned list. Low risk. Anti-inflammatory benefit could support recovery.

  • Sleep-disordered
    OPTIONAL-ADD

    Modest sleep aid via GABA-A. Better evidence base for chamomile *extract* than for isolated apigenin specifically. Stack with magnesium glycinate/threonate + theanine + tryptophan for layered sleep support.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    Anti-inflammatory + senomorphic story is appealing post-injury but evidence remains preclinical.

  • Strength/anabolic-focused
    CAUTION

    Aromatase inhibition is the lever that bodybuilders sometimes intentionally pull (estrogen control on cycle). Outside that context, dropping endogenous estradiol modestly is anti-anabolic in the long run (E is required for joints, lipids, libido, bone). Risk modest at 50-100 mg/day; meaningful at 200+ mg chronic. Verdict for natural lifters not on cycle: skip or low-dose only.

▸ Subjective experience (deep)

Most users at 50 mg report nothing noticeable. This is consistent with the bioavailability problem and the mild GABA-A binding affinity.

At 200 mg+ (or with liposomal 50-100 mg), reports cluster around:

  • Mild calm / "background quiet" 30-90 minutes after dose
  • Slight drowsiness if taken evening (the basis for the Huberman pre-bed protocol)
  • Easier sleep onset for some, especially when stacked with magnesium + theanine
  • Vivid dreams occasionally reported
  • No stimulant-like or pro-cognitive felt effect — anyone reporting a sharp "nootropic" boost at dietary doses is likely placebo

Onset: 30 min – 2.5 hr (Tmax). Half-life: ~2.5 hr → effect wanes within 4-6 hr.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal / unknown. No tolerance signal in any chronic-dosing study. CD38 enzyme inhibition is not classically downregulating. GABA-A binding is weak enough that benzodiazepine-style tolerance is not expected at supplemental doses.
  • Recommended cycle: Daily, no cycling needed. Encyclopedia agrees.
  • Reset protocol if needed: Not applicable. If estradiol drops too low, discontinue and recheck in 4-6 weeks.
▸ Stacking deep dive

Synergistic with

  • nad-plus precursors (NMN, NR): The complementary thesis — apigenin slows NAD+ destruction (CD38 inhibition) while NMN/NR raise NAD+ supply. Sinclair-lab framework explicitly endorses this combo.
  • taurine: Both are GABA-A positive modulators with weak affinity → mild additive calm without sedation. Both anti-excitotoxic, theoretically helpful for impact recovery (MMA).
  • l-tryptophan: Pre-bed sleep stack. Tryptophan → serotonin → melatonin while apigenin contributes mild GABA-A tone. Logical Dylan V5 stack: apigenin + tryptophan + magnesium glycinate/threonate evening.
  • astaxanthin: Both lipid-soluble antioxidants; complementary anti-inflammatory pathways (apigenin = NLRP3, astaxanthin = mitochondrial ROS scavenging).
  • foxo4-dri (theoretical): FOXO4-DRI is a classical senolytic; apigenin is senomorphic. Conceptually you'd run senolytic in pulses + senomorphic chronically. No human data on combining, purely theoretical.
  • curcumin (already V4): Both anti-inflammatory, both flavonoid-class, no interaction concern, reinforcing.
  • theanine: GABA modulation + glutamate modulation pair well for evening calm.

Avoid stacking with

  • Pharmaceutical aromatase inhibitors (anastrozole, letrozole, exemestane) — additive estradiol suppression. Not relevant for Dylan but flag for anyone on AI therapy.
  • Other strong aromatase-inhibiting flavonoids (chrysin high-dose, some grape-skin extracts) — same additive concern.
  • CYP3A4-substrate drugs at narrow therapeutic index (see Drug interactions). Not a stacking issue per se but worth flagging.
  • Tamoxifen / SERMs: Apigenin's biphasic ER activity could interfere; oncology patients on these drugs should consult oncologist.

Neutral / safe co-administration

  • Modafinil (no known interaction; mechanism non-overlapping)
  • Bromantane, Semax, Selank, Adamax (no overlap)
  • Cerebrolysin (complementary neuroprotection)
  • All V4 components: NAC, citicoline, magnesium, fish oil, PS, rhodiola, theanine, glycine, vitamin D, beta-alanine, vitamin C, creatine — no concerns.
  • Caffeine (no interaction; opposing wake/calm not pharmacological)
▸ Drug interactions deep dive

Apigenin inhibits multiple CYP enzymes — human in-vivo significance is debated because oral bioavailability is poor, but the inhibition is real and matters for high-dose users or those on narrow-therapeutic-index drugs.

  • CYP3A4: Reversible inhibition, reported IC50 ~0.4 µM. Clinically modest. Drugs to watch: many statins (simvastatin, atorvastatin), some calcium channel blockers, midazolam, alfentanil, immunosuppressants (cyclosporine, tacrolimus), some cancer drugs (imatinib — apigenin shown to increase imatinib AUC in rats).
  • CYP2C9: Inhibition reported. Drugs to watch: warfarin (bleeding risk), NSAIDs, fluvastatin, sulfonylureas, irbesartan, losartan.
  • CYP1A2: Inhibition reported. Drugs to watch: caffeine (could mildly raise caffeine levels — Dylan's caffeine ramp is relevant), theophylline, clozapine, olanzapine.
  • P-glycoprotein: Some inhibition; relevant for digoxin, some chemo drugs.
  • Hormonal drugs: Combined OCPs / HRT — theoretical interaction via aromatase + ER pathways. Monitor.
  • Anticoagulants/antiplatelets: Theoretical mild bleeding risk via platelet pathways + CYP2C9/warfarin. Monitor INR if relevant.

For Dylan: not on any of these drugs. The caffeine + apigenin combination is mild — apigenin's CYP1A2 inhibition could nudge caffeine half-life slightly upward, possibly amplifying his caffeine ramp slightly. Negligible at 50 mg apigenin pre-bed (caffeine should already be cleared by then).

▸ Pharmacogenomics
  • CYP3A4/CYP3A5 polymorphisms: Carriers of CYP3A5 *3 (poor expressers — common in white populations including Nordic ancestry) already have lower CYP3A activity; adding apigenin compounds the inhibition. Practical effect: more cumulative drug exposure for any CYP3A4 substrate co-administered.
  • **CYP2C9 2/3 carriers (slow metabolizers): Higher exposure/effect for CYP2C9 substrates when combined with apigenin. Relevant if Dylan ever takes warfarin or NSAIDs chronically.
  • *CYP1A2 1F (rapid inducer phenotype, common in white/Nordic): Faster baseline caffeine clearance — apigenin's mild CYP1A2 inhibition could partially counteract this.
  • COMT Val158Met: No direct apigenin interaction, but Val/Val (slow methylators) might subjectively feel apigenin's calming effect more clearly given baseline higher dopamine/norepinephrine.
  • Once 23andMe results land (~June 2026): check CYP3A5, CYP1A2, CYP2C9 status for Dylan. If poor metabolizer phenotype, consider lower apigenin dose or split dosing.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC supplement Nootropics Depot — 50 mg ×180 caps OR 200 mg ×120 caps ~$20-40/bottle, ~$8-15/mo at 50 mg/day high 98%+ purity, third-party tested. Standard powder, not liposomal. Encyclopedia top pick.
OTC supplement Toniiq Liposomal Apigenin — 100 mg ×180 caps $29.97 ($25.47 sub) → ~$15-30/mo high Liposomal — solves the bioavailability problem. At 50 mg/day = ~$15/mo. Best form-factor pick.
OTC supplement Double Wood Apigenin — 50 mg ×120 caps $24.95/bottle = ~$6/mo at 50 mg/day medium-high Cheapest reputable option. Standard powder, no liposomal.
OTC supplement Pure Bulk apigenin powder ~$10-20 / 5-10g, ~$3-8/mo medium Cheap bulk powder; weigh own doses. No liposomal.
OTC supplement iHerb — various brands varies, ~$10-20/mo medium Easy add to existing iHerb V4 cart. Verify purity claims.
Phytosome APLC (research-grade) — limited consumer products varies medium 36× solubility increase vs base apigenin (Telang 2016). Few consumer SKUs.

Recommendation for Dylan: Toniiq Liposomal 100 mg every other day OR daily ($15-30/mo). If price-sensitive, Double Wood 50 mg standard powder ($6/mo) but accept under-dosing for systemic effects (still gets some GABA-A action since brain delivery is local-receptor not systemic-AUC dependent).

▸ Biomarkers to track (deep)
  • Baseline (before starting):
    • Total + free testosterone
    • Estradiol (sensitive assay — LC-MS/MS preferred for men, range 10-40 pg/mL)
    • SHBG
    • hs-CRP, IL-6 (inflammation baseline)
    • Liver panel (ALT, AST, ALP)
    • For longevity pass: NAD+ if testable (Jinfiniti or similar)
  • During use: Re-check estradiol + testosterone at 12 weeks if dosing ≥100 mg/day. Liver panel if any GI symptoms or jaundice (precaution; clinical risk minimal).
  • Subjective (cheap, daily): Sleep quality (PSQI weekly or Oura/Whoop trend), libido, morning erection frequency, joint comfort, mood (GAD-7 monthly).
  • Post-cycle: N/A — daily dosing protocol.
▸ Controversies / open debates Live debate

  • Sinclair lab's CD38/apigenin thesis vs. translational reality: The 2013 paper showed mouse hepatic NAD+ doubled with IP apigenin. Oral apigenin's poor bioavailability means most humans at 50-200 mg oral may not reach the tissue concentrations needed. No human NAD+ data exists for oral apigenin specifically. The longevity claim rests on solid mechanism + animal evidence + zero human verification.

  • Senolytic vs. senomorphic confusion: Older literature (and many supplement marketers) call apigenin "senolytic." 2024-2025 work clarifies it's senomorphic — suppresses SASP rather than killing senescent cells. This matters because senolytics are dosed in pulses (FOXO4-DRI, dasatinib + quercetin) while senomorphics are dosed chronically. Consumer messaging hasn't caught up.

  • "50 mg human attention study" claim: The Dylan encyclopedia and several supplement vendors cite a 50 mg human study showing attention/concentration improvement. I cannot verify a published, peer-reviewed clinical trial of isolated apigenin at 50 mg for cognition. A 2024 systematic review (PMC10813036) explicitly states no clinical trials test apigenin for cognitive aging. This may be a mis-citation propagated from a chamomile-extract study or a low-quality unblinded vendor trial. Flag for accuracy review.

  • Aromatase concern in healthy young men: No human RCT measures estradiol changes in healthy young men taking apigenin chronically. Concern is mechanistic (in vitro IC50 ~2.9 µM) extrapolation. Real-world risk at 50 mg likely small but non-zero.

  • Bioavailability claims vs. consumer reality: Vendors selling standard powdered apigenin imply equivalent benefit to liposomal forms — pharmacokinetic studies show 3-4× AUC differences. Most users at 50 mg standard powder are likely in the "barely measurable in plasma" zone for systemic effects, even if local GABA-A tone in CNS is reachable.

  • Clinical-trial gap: Despite ~30 years of preclinical work, isolated apigenin has minimal human trial coverage. Chamomile extract data is the practical bridge but doesn't isolate apigenin's contribution.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-ADD, MEDIUM confidence. Mechanism story strong, human evidence thin, bioavailability is the dominant problem. Recommend liposomal form (Toniiq) over standard 50 mg powder if Dylan wants a real shot at systemic CD38/NAD+ effects. Risk profile clean enough that even minimal benefit justifies the $6-30/mo cost.
▸ Open questions / gaps Open
  • No human PK/PD study at supplemental doses with NAD+ measurement. The whole longevity thesis hinges on NAD+ preservation that has only been measured in mouse liver after IP injection. A 12-week human RCT measuring serum/intracellular NAD+ with oral 50/100/200 mg apigenin — standard vs. liposomal — would settle the basic question.
  • No human estradiol-impact study in young healthy men. Chronic 100-200 mg apigenin × 12 weeks measuring estradiol/testosterone/SHBG would close the safety gap for athletes/bodybuilders.
  • No human cognitive RCT. The "50 mg attention study" cited in the encyclopedia needs verification; if it doesn't exist, that line should be corrected.
  • Liposomal apigenin pricing/quality landscape is shallow. Toniiq is the main consumer SKU; would benefit from second/third reputable competitor (Quicksilver, Designs for Health, etc. don't currently carry it).
  • CD38 inhibitor combinatorial therapy: No data on apigenin + NMN vs. either alone in humans. The Sinclair-lab logic strongly suggests synergy but it's untested.
  • Quercetin/EGCG family overlap: Apigenin overlaps mechanistically with quercetin (also CD38 inhibitor + senolytic-adjacent) and EGCG (anti-inflammatory + CYP inhibitor). Stacking three flavonoids that all inhibit CYP3A4/CYP2C9 amplifies drug-interaction risk. Open question whether running apigenin + quercetin + EGCG provides more benefit than any one alone.
▸ Sources (full, with our context)
Back to compact view